[go: up one dir, main page]

GT199900067A - Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica. - Google Patents

Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.

Info

Publication number
GT199900067A
GT199900067A GT199900067A GT199900067A GT199900067A GT 199900067 A GT199900067 A GT 199900067A GT 199900067 A GT199900067 A GT 199900067A GT 199900067 A GT199900067 A GT 199900067A GT 199900067 A GT199900067 A GT 199900067A
Authority
GT
Guatemala
Prior art keywords
new
prurtic
dedermatosis
phenylpiperidines
treatment
Prior art date
Application number
GT199900067A
Other languages
English (en)
Inventor
Richard Edward Armer
Christopher James Dutton
David Morris Gethin
Julian Duncan Smith
Stephen Paul Gibson
Ivan Tommasini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900067A publication Critical patent/GT199900067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

CONFORME A LA PRESENTE INVENCIÒN, SE PROPORCIONAN NUEVAS 4FENILPIPERIDINAS QUE SON AGENTES ANTIPRURÌTICOS POTENTES Y EFICACES. LA ESTRUCTURA DE ÈSTOS COMPUESTOS SE MUESTRAN ABAJO COMO FÒRMULA (I), DONDE LAS LETRAS: "O,R,X & Y" SON SÌMBOLOS DE LOS GRUPOS QUE PUEDEN EXISTIR DENTRO LA ESTRUCTURA GENERAL LOS CUALES SE
GT199900067A 1998-05-18 1999-05-14 Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica. GT199900067A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810671.9A GB9810671D0 (en) 1998-05-18 1998-05-18 Anti-pruritic agents

Publications (1)

Publication Number Publication Date
GT199900067A true GT199900067A (es) 2000-11-04

Family

ID=10832267

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900067A GT199900067A (es) 1998-05-18 1999-05-14 Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.

Country Status (18)

Country Link
US (1) US6610711B2 (es)
EP (1) EP1077940B1 (es)
JP (1) JP2002515486A (es)
AP (1) AP9901535A0 (es)
AT (1) ATE271038T1 (es)
AU (1) AU3531299A (es)
BR (1) BR9910609A (es)
CA (1) CA2332538C (es)
DE (1) DE69918687T2 (es)
DK (1) DK1077940T3 (es)
ES (1) ES2230846T3 (es)
GB (1) GB9810671D0 (es)
GT (1) GT199900067A (es)
MA (1) MA26630A1 (es)
PT (1) PT1077940E (es)
TN (1) TNSN99095A1 (es)
WO (1) WO1999059971A1 (es)
ZA (1) ZA993364B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EA005934B1 (ru) * 2001-07-05 2005-08-25 Х. Лундбекк А/С Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
AP1816A (en) * 2001-10-22 2008-01-04 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
NZ533158A (en) * 2001-11-19 2006-09-29 Elan Pharm Inc 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines
ES2201908B1 (es) * 2002-05-29 2005-02-16 Laboratorios Del Dr. Esteve, S.A. Pienso suplementado con ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
WO2006089082A2 (en) * 2005-02-17 2006-08-24 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals
EP1966132A2 (en) * 2005-12-15 2008-09-10 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EA200900403A1 (ru) * 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
DE602008005771D1 (de) * 2007-08-27 2011-05-05 Theravance Inc Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
WO2009029253A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2185553B1 (en) * 2007-08-27 2012-06-27 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009061652A1 (en) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2010005782A1 (en) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
US8383651B2 (en) * 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN106278914B (zh) * 2016-08-19 2018-04-13 四川福思达生物技术开发有限责任公司 一种增产胺的合成工艺
CN116440882B (zh) * 2023-01-16 2024-09-20 浙江纽龙合成材料制造有限公司 一种基于端烯基活化的疏水分离层析介质及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
PH24752A (en) 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
JP2001526643A (ja) * 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環

Also Published As

Publication number Publication date
US20030078282A1 (en) 2003-04-24
WO1999059971A1 (en) 1999-11-25
JP2002515486A (ja) 2002-05-28
GB9810671D0 (en) 1998-07-15
ZA993364B (en) 2000-12-01
CA2332538C (en) 2005-08-02
TNSN99095A1 (fr) 2005-11-10
MA26630A1 (fr) 2004-12-20
BR9910609A (pt) 2001-01-09
DK1077940T3 (da) 2004-11-01
CA2332538A1 (en) 1999-11-25
ATE271038T1 (de) 2004-07-15
PT1077940E (pt) 2004-10-29
DE69918687T2 (de) 2005-07-28
DE69918687D1 (de) 2004-08-19
ES2230846T3 (es) 2005-05-01
US6610711B2 (en) 2003-08-26
AP9901535A0 (en) 1999-06-30
EP1077940B1 (en) 2004-07-14
AU3531299A (en) 1999-12-06
EP1077940A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
CR6592A (es) Compuestos para el tratamiento de la isquemia
ES2114882T3 (es) Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
ES2192201T3 (es) Compuestos de piranona utiles para el tratamiento de infecciones retrovirales.
ES2172585T3 (es) Derivado de benzoimidazol.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2176329T3 (es) Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
PA8493701A1 (es) Compuestos para tratar la obesidad
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
ES2119912T3 (es) Nuevos aminometilenpeptidos como inmunosupresores.
AR027355A1 (es) Acidos tiazolidincarboxilicos
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2113368T3 (es) Antagonistas de serotonina.
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2072263T3 (es) Derivados de 4-aminopiridina.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
MXPA94001345A (es) Derivados de poliamina como agentes radioprotectores.
ES2123873T3 (es) Pirrolocarbazol.